Park Ha Biological Technology Co Ltd (PHH) FinancialsPHHPark Ha Biological Technology Co Ltd

Evaluating the bottom line, Park Ha Biological Technology Co Ltd maintains a gross margin of 95.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1591.00%, while the net margin is -1600.71%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PHH converts its operational activities into shareholder value.

In the context of the broader market, PHH competes directly with industry leaders such as AXIL and NHTC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, PHH's gross margin of 95.28% stands against AXIL's 72.02% and NHTC's 75.25%. Such benchmarking helps identify whether Park Ha Biological Technology Co Ltd is trading at a premium or discount relative to its financial performance.